Phenotypes associated with this allele

• Allele Symbol: Col1a1^{tm4(CAG-FGFR2_iIIIb*K660N)Kkw}
• Allele Name: targeted mutation 4, Kwok-Kin Wong
• Allele ID: MGI:5661319
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Col1a1^tm4(CAG-FGFR2_iIIIb*K660N)Kkw/Col1a1^+	involves: 129S4/SvJae * BALB/c * C57BL/6	MGI:5661329
cn2	Col1a1^tm4(CAG-FGFR2_iIIIb*K660N)Kkw/Col1a1^+ Trp53^tm1Brn/Trp53^tm1Brn	involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6	MGI:5661330

Genotype
MGI:5661329

cn1

• Allelic Composition: Col1a1^{tm4(CAG-FGFR2_iIIIb*K660N)Kkw}/Col1a1⁺
• Genetic Background: involves: 129S4/SvJae * BALB/c * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased lung tumor incidence ( J:214230 )

• 40% of mice develop lung tumors with an average latency of about 64 weeks after intranasal delivery of an adenovirus expressing cre recombinase

respiratory system

increased lung tumor incidence ( J:214230 )

• 40% of mice develop lung tumors with an average latency of about 64 weeks after intranasal delivery of an adenovirus expressing cre recombinase

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
lung cancer		DOID:1324	OMIM:211980 OMIM:608935 OMIM:612571 OMIM:612593 OMIM:614210	J:214230

Genotype
MGI:5661330

cn2

• Allelic Composition: Col1a1^{tm4(CAG-FGFR2_iIIIb*K660N)Kkw}/Col1a1⁺; Trp53^tm1Brn/Trp53^tm1Brn
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6

neoplasm

increased lung tumor incidence ( J:214230 )

• 92% of mice develop lung tumors with a latency of 28-32 weeks after intranasal delivery of an adenovirus expressing cre recombinase (Ad-cre)

• mice with lung tumors treated with a pan-FGFR inhibitor, BGJ-398, mice show more than 50% tumor regression

increased lung adenocarcinoma incidence ( J:214230 )

• tumors from Ad-cre treated mice resemble poorly differentiated human grade 3/4 lung adenocarcinoma displaying high pleiotropy and heavily multinucleated tumor cells showing local invasion throughout the lung parenchyma

growth/size/body

weight loss ( J:214230 )

• Ad-cre treated mice that become sick present with weight loss

mortality/aging

premature death ( J:214230 )

• mice show a decrease in overall survival after Ad-cre treatment, beginning to die around 20 weeks after Ad-cre delivery and most dying by 50 weeks after Ad-cre administration

respiratory system

increased lung tumor incidence ( J:214230 )

• 92% of mice develop lung tumors with a latency of 28-32 weeks after intranasal delivery of an adenovirus expressing cre recombinase (Ad-cre)

• mice with lung tumors treated with a pan-FGFR inhibitor, BGJ-398, mice show more than 50% tumor regression

increased lung adenocarcinoma incidence ( J:214230 )

• tumors from Ad-cre treated mice resemble poorly differentiated human grade 3/4 lung adenocarcinoma displaying high pleiotropy and heavily multinucleated tumor cells showing local invasion throughout the lung parenchyma

respiratory distress ( J:214230 )

• Ad-cre treated mice that become sick present with progressive dyspnea and weight loss

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
lung cancer		DOID:1324	OMIM:211980 OMIM:608935 OMIM:612571 OMIM:612593 OMIM:614210	J:214230